Show simple item record

dc.contributor.authorStarska, Katarzyna
dc.contributor.authorForma, Ewa
dc.contributor.authorBrzezińska-Błaszczyk, Ewa
dc.contributor.authorLewy-Trenda, Iwona
dc.contributor.authorBryś, Magdalena
dc.contributor.authorJóźwiak, Paweł
dc.contributor.authorKrześlak, Anna
dc.description.abstractAberrant protein O-GlcNAcylation may contribute to the development and malignant behavior of many cancers. This modification is controlled by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAcase (OGA). The aim of this study was to determine the expression of O-GlcNAc cycling enzymes mRNA/protein and to investigate their relationship with clinicopathological parameters in laryngeal cancer. The mRNA levels of OGT and MGEA5 genes were determined in 106 squamous cell laryngeal cancer (SCLC) cases and 73 non-cancerous adjacent laryngeal mucosa (NCLM) controls using quantitative real-time PCR. The level of OGT and OGA proteins was analyzed by Western blot. A positive expression of OGT and MGEA5 transcripts and OGT and OGA proteins was confirmed in 75.5 and 68.9 % and in 43.7 and 59.4 % samples of SCLC, respectively. Higher levels of mRNA/protein for both OGT and OGA as well as significant increases of 60 % in total protein O-GlcNAcylation levels were noted in SCLC compared with NCLM (p < 0.05). As a result, an increased level of OGT and MGEA5 mRNA was related to larger tumor size, nodal metastases, higher grade and tumor behavior according to TFG scale, as well as incidence of disease recurrence (p < 0.05). An inverse association between OGT and MGEA5 transcripts was determined with regard to prognosis (p < 0.05). In addition, the highest OGT and OGA protein levels were observed in poorly differentiated tumors (p < 0.05). No correlations with other parameters were noted, but the results showed a trend of more advanced tumors to be more frequently OGT and OGA positive. The results suggest that increased O-GlcNAcylation may have an effect on tumor aggressiveness and prognosis in laryngeal cancer.pl_PL
dc.description.sponsorshipThis work was supported, in part, by a grant from the National Science Council, Poland (N403 043 32/2326), by the statutory fund of the Department of Cytobiochemistry, University of Łódź, Poland (506/811)pl_PL
dc.publisherSpringer International Publishingpl_PL
dc.relation.ispartofseriesClinical and Experimental Medicine;4
dc.rightsUznanie autorstwa 3.0 Polska*
dc.subjectOGA (MGEA5)pl_PL
dc.subjectTumor front grading (TFG)pl_PL
dc.subjectLaryngeal cancerpl_PL
dc.titleGene and protein expression of O-GlcNAc-cycling enzymes in human laryngeal cancerpl_PL
dc.contributor.authorAffiliationUniversity of Łódź, Department of Cytobiochemistrypl_PL
dc.contributor.authorAffiliationMedical University of Łódźpl_PL
dc.referencesVaidyanathan K, Durning S, Wells L. Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology. Crit Rev Biochem Mol Biol. 2014;49(2):140–63pl_PL
dc.referencesGloster TM, Vocadlo DJ. Mechanism, structure, and inhibition of O-GlcNAc processing enzymes. Curr Signal Transduct Ther. 2010;5(1):74–91pl_PL
dc.referencesOzcan S, Andrali SS, Cantrell JE. Modulation of transcription factor function by O-GlcNAc modification. Biochim Biophys Acta. 2010;1799(5–6):353–64pl_PL
dc.referencesMa J, Hart GW. O-GlcNAc profiling: from proteins to proteomes. Clin Proteomics. 2014;11(1):8. doi:10.​1186/​1559-0275-11-8pl_PL
dc.referencesBond MR, Hanover JA. O-GlcNAc cycling: a link between metabolism and chronic disease. Annu Rev Nutr. 2013;33:205–29pl_PL
dc.referencesFardini Y, Dehennaut V, Lefebvre T, Issad T. O-GlcNAcylation: a new cancer hallmark? Front Endocrinol (Lausanne). 2013;4:99. doi:10.​3389/​fendo.​2013.​00099pl_PL
dc.referencesMa Z, Vosseller K. O-GlcNAc in cancer biology. Amino Acids. 2013;45(4):719–33pl_PL
dc.referencesSlawson C, Hart GW. O-GlcNAc signalling: implications for cancer cell biology. Nat Rev Cancer. 2011;11(9):678–84pl_PL
dc.referencesLi Z, Yi W. Regulation of cancer metabolism by O-GlcNAcylation. Glycoconj J. 2013;31(3):185–91pl_PL
dc.referencesOlivier-Van Stichelen S, Dehennaut V, Buzy A, et al. O-GlcNAcylation stabilizes β-catenin through direct competition with phosphorylation at threonine 41. FASEB J. 2014;28(8):3325–38pl_PL
dc.referencesItkonen HM, Minner S, Guldvik IJ, et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res. 2013;73(16):5277–87pl_PL
dc.referencesCooks T, Pateras IS, Tarcic O, et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23(5):634–46pl_PL
dc.referencesBlandino G, Deppert W, Hainaut P, et al. Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death Differ. 2012;19(1):180–3pl_PL
dc.referencesMa Z, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J Biol Chem. 2013;288(21):15121–30pl_PL
dc.referencesKawauchi K, Araki K, Tobiume K, Tanaka N. Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification. Proc Natl Acad Sci USA. 2009;106(9):3431–6pl_PL
dc.referencesGu Y, Mi W, Ge Y, et al. GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res. 2010;70(15):6344–51pl_PL
dc.referencesPark SY, Kim HS, Kim NH, et al. Snail1 is stabilized by O-GlcNAc modification in hyperglycaemic condition. EMBO J. 2010;29(22):3787–96pl_PL
dc.referencesLynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 2012;287(14):11070–81pl_PL
dc.referencesZhu Q, Zhou L, Yang Z, et al. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol. 2012;29(2):985–93pl_PL
dc.referencesCaldwell SA, Jackson SR, Shahriari KS, et al. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene. 2010;29(19):2831–42pl_PL
dc.referencesKamigaito T, Okaneya T, Kawakubo M, Shimojo H, Nishizawa O, Nakayama J. Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis. 2014;17(1):18–22pl_PL
dc.referencesHuang X, Pan Q, Sun D, et al. O-GlcNAcylation of cofilin promotes breast cancer cell invasion. J Biol Chem. 2013;288(51):36418–25pl_PL
dc.referencesPhueaouan T, Chaiyawat P, Netsirisawan P, et al. Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer. Oncol Rep. 2013;30(6):2929–36pl_PL
dc.referencesRozanski W, Krzeslak A, Forma E, et al. Prediction of bladder cancer based on urinary content of MGEA5 and OGT mRNA level. Clin Lab. 2012;58(5–6):579–83pl_PL
dc.referencesYehezkel G, Cohen L, Kliger A, Manor E, Khalaila I. O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-β-D-glucosaminidase silencing on cell phenotype and transcriptome. J Biol Chem. 2012;287(34):28755–69pl_PL
dc.referencesMi W, Gu Y, Han C, et al. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta. 2011;1812(4):514–9pl_PL
dc.referencesKrześlak A, Wójcik-Krowiranda K, Forma E, Bieńkiewicz A, Bryś M. Expression of genes encoding for enzymes associated with O-GlcNAcylation in endometrial carcinomas: clinicopathologic correlations. Ginekol Pol. 2012;83(1):22–6pl_PL
dc.referencesSlawson C, Pidala J, Potter R. Increased N-acetyl-beta-glucosaminidase activity in primary breast carcinomas corresponds to a decrease in N-acetylglucosamine containing proteins. Biochim Biophys Acta. 2001;1537(2):147–57pl_PL
dc.referencesEdge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4pl_PL
dc.referencesStarska K, Kulig A, Lukomski M. Tumor front grading in prediction of survival and lymph node metastases in patients with laryngeal carcinoma. Adv Med Sci. 2006;51:200–4pl_PL
dc.referencesChampattanachai V, Netsirisawan P, Chaiyawat P, et al. Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer. Proteomics. 2013;13(14):2088–99pl_PL
dc.referencesPhoomak C, Silsirivanit A, Wongkham C, Sripa B, Puapairoj A, Wongkham S. Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma. Asian Pac J Cancer Prev. 2012;13(Suppl):101–5pl_PL
dc.referencesVocadlo DJ. O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation. Curr Opin Chem Biol. 2012;16(5–6):488–97pl_PL
dc.referencesMacauley MS, Vocadlo DJ. Enzymatic characterization and inhibition of the nuclear variant of human O-GlcNAcase. Carbohydr Res. 2009;344(9):1079–84pl_PL
dc.referencesKeembiyehetty CN, Krzeslak A, Love DC, Hanover JA. A lipid-droplet-targeted O-GlcNAcase isoform is a key regulator of the proteasome. J Cell Sci. 2011;124(16):2851–60pl_PL
dc.referencesWhisenhunt TR, Yang X, Bowe DB, Paterson AJ, Van Tine BA, Kudlow JE. Disrupting the enzyme complex regulating O-GlcNAcylation blocks signaling and development. Glycobiology. 2006;16(6):551–63pl_PL
dc.referencesKreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem. 1997;272(14):9308–15pl_PL
dc.referencesJin H, Xu M, Padakanti PK, Liu Y, Lapi S, Tu Z. Preclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging. Mol Pharm. 2013;10(10):3655–64pl_PL

Files in this item


This item appears in the following Collection(s)

Show simple item record

Uznanie autorstwa 3.0 Polska
Except where otherwise noted, this item's license is described as Uznanie autorstwa 3.0 Polska